Evidence map›Paper›PMID 40331188›Full record

ArticleFrontiers in pharmacology2025

RNF180 weakened the lipid droplet formation and subsequent chemoresistance by destabilizing ACC1 and ACLY in esophageal cancer.

Ning Li, Dao-Fu Shen, Nan-Chang Yin, Zheng-Guo Cui, Hua-Chuan Zheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ning LiCenter of Translational Medicine and Cancer Center, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Dao-Fu ShenDepartment of Clinical Laboratory, Chifeng Municipal Hospital, Chifeng, China.
Nan-Chang YinDepartment of Thoracic Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Zheng-Guo CuiDepartment of Environmental Health, University of Fukui School of Medical Sciences, Fukui, Japan.
Hua-Chuan ZhengCenter of Translational Medicine and Cancer Center, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: RNF180 (Ring finger protein 180) is an E3 ubiquitin-protein ligase that promotes polyubiquitination and proteasomal degradation. The study aimed to clarify the clinicopathological significances, signal pathways and molecular mechanisms of RNF180 expression in esophageal cancer. Methods: We analyzed the clinicopathological significances and signal pathways of RNF180 expression in esophageal cancer (EC) through bioinformatics and pathological analysis. We also clarified its effects on aggressiveness and related molecular mechanisms Results: RNF180 mRNA expression was lower in EC than in normal tissues (p < 0.05), opposite for its methylation (p < 0.05). Conclusion:

Indexed as

aggressivenessdrug resistanceesophageal cancerlipid droplet formationRNF180target therapy

Identifiers

PMID40331188
PMCPMC12052773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.